Acutus Medical, Inc. (AFIB) saw a sudden decline of 20.42% in aftermarket following the initiation of AcQForce PFA-CE. However, the last trading session closed at $6.66 with a decrease of 9.88%.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Initiation of AcQForce PFA-CE – A Great Turnaround!
On 11th November 2021, AFIB announced the initiation of AcQForce PFA-CE which is a new randomized controlled trial. This research will assess the safety and effectiveness of the company’s focused force-sensing Pulsed Field Ablation (PFA) catheter and system in conjunction with its unique non-contact 3D mapping technology in treatment with atrial fibrillation.
The capacity of Pulsed Field Ablation to provide high-impact therapy while conserving healthy tissue was a major factor in the development of this treatment. Most physicians know that the majority of the patient populations who return for re-treatment after ablation for atrial fibrillation have trigger points in various locations far beyond the standard process of treatment, and it has been absolutely essential now to study beyond pulmonary vein isolation-only utilizations.
The volume and outlines of PFA lesions obey well-defined and predictable electromagnetic laws, and the technique is well-suited for incorporation into 3D mapping systems like AcQMap. When ablating particular parts of the heart, including and outside the pulmonary veins, this prepares the way for a better degree of precision and efficacy.
AFIB is aiming toward a time when they will be able to swiftly construct a 3D electroanatomic map of a complicated arrhythmia like atrial fibrillation and give accurate, customized, and long-lasting treatment with greatly enhanced safety, dependability, and workflow.
Third Quarter 2021 Financial Results – Was the quarter strong enough?
AFIB released third-quarter 2021 financial results on 11th November 2021. The third quarter of 2021 brought in $4.6 million in revenue, which is $3.2 million more than the previous year. Moreover, increased direct AFIB disposables sales and greater procedure volumes, as well as increased distributor sales through Biotronik, drove the rise over the same quarter last year. In addition, the GAAP gross margin was negative 86 percent, compared to negative 62 percent the previous year.
On a GAAP basis, operating expenditures for the third quarter of 2021 were $23.2 million, compared to $24.3 million in the same quarter the previous year. The decline was principally due to a change in the fair value of the contingent consideration connected to the purchase of Rhythm Xience, which was somewhat offset by increases from AFIB’s research and development team expansion.
Company’s Opinions Stated
AFIB enhanced its portfolio and market position in the left heart access, mapping and therapy guiding, and therapy categories throughout the quarter. Furthermore, electrophysiologists and structural heart experts have praised the novel left heart access product line, and they are continuing to develop their offerings in this area.
Last but not least, the software team developed a first-in-industry mapping software upgrade with the automatic region of interest locators to enable physicians better personalize their therapy for each patient while reducing the damage of good tissue.